Aarkstore Enterprise -The Market Outlook for Neurodegenerative Diseases: Epidemiology, market size,

The Market Outlook for Neurodegenerative Diseases: Epidemiology

, market size, current treatments and future innovation.

Each year over 10 million people globally suffer from neurodegenerative diseases (ND). This figure is expected to grow by 20% over the next decade as the aging population increases and lives longer. Such population growth translates to an expanded therapeutic market for key NDs, including Alzheimers, Parkinsons, multiple sclerosis, Huntingtons, and amyotrophic lateral sclerosis because of increased prevalence, associated medical treatment costs, and demand for more effective new treatments. In a highly competitive environment, understanding the market dynamics of the ND therapy area is crucial for product development to enable benchmarking and strategic planning in context of the pipeline and established market forces.

In a sector currently estimated at reaching $20bn by 2014, long-term sustainable growth opportunities in ND are anticipated based on increasing diagnoses of these disorders, increased genericization, and novel late-stage products and technologies.

This report explores novel therapeutics that show promise to widen the therapeutic options for ND and also highlights the key commercialisation activities and developments of major players.

This report hence offers essential market insight on the research and development trends for the ND area providing a rapid understanding of current therapeutics, their advantages and disadvantages, and the important pipeline candidates most likely to succeed in the marketplace. Additionally, this report provides a comprehensive assessment of current and future pharmacological and novel cell-based treatments for these diseases and updates the reader on pathophysiology, epidemiology, pipeline research, product evaluations, and commercial opportunities. The report also outlines the key drivers and inhibitors of drug development in each sector with detailed analysis based on primary and secondary research.

Key features of this report

In-depth analyses of disease epidemiology, pathobiology, products, pipelines, and commercial opportunities in neurodegenerative diseases

Evaluation of the R&D clusters and themes in ND drug development.

Identifies the current trends in product and clinical development.

Detailed assessment of leading products in Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and Parkinson's disease.

Analysis of novel cell therapies for ND and how they may impact on traditional drug development

Comprehensive coverage of drug classes currently marketed and in the pipeline for major NDs

Market analysis of current and future therapy areas to 2014

Identification and evaluation of leading products and market opportunities in neurodegenerative diseases

Therapy area forecasts and sector opportunities in an increasingly competitive landscape.

Key benefits from reading this report

Understand the basis to NDs and key prevalence and aetiology data driving drug development

Up-to-date information on products, activities, and companies driving innovations in the field.

Shows how drug development is progressing and the risks involved in developing drugs for NDs

Identifies product successes and failures and details current sales for leading drugs with forecasts to 2014 for established and pipeline candidates

Provides analyses and commentary on trends in research, clinical development, and marketing activities of products.

Enables rapid assessment of the scope of activity in the field and how innovations may radically change the face of therapeutics in the next 5-10 years.

Shows forecasts of leading products and new entrants to market to enable product positioning and scenario building

Provides market insight on the current and future landscape for ND treatments.

Key findings of this report

Innovation in NDs is creating a rich pipeline of traditional and cell-based treatments for Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and Parkinson's disease .

Novel biologics such as monoclonal antibodies and other immunotherapies may significantly expand the ND market within the next decade.

Demand for new treatments is driven by increasing prevalence, genericisation, cost-containment, and limitations of current products.

Orphan diseases such as ALS and HD are under-served in R&D and represent high-growth sector opportunities; however, the pipeline may fulfil unmet needs in the near-term for these diseases stimulating market growth and expansion.

Prevalence will increase for major NDs by 20% over the next decade, combined with enlarging ageing population, which will drive growth in the market. However, growth will be tempered by generic substitution and innovations if approved.

ND drug development is risky with high attrition rates but if sectors may experience significant growth such as in AD if new biologics in late-stage development are approved.

Introduction of stem cell-based therapies may radically change the treatment approaches for NDs. Current clinical developments for cell therapies are promising with a number of therapy areas in mid-term phases of development.

Established therapeutic classes of centrally-acting drugs for NDs may be superseded by novel immunotherapies and cell-based treatments that offer new therapeutic approaches that will change the market dynamics significantly.

Key questions answered by this report

1. What are the major NDs and how are they currently treated?

2. What is the global prevalence of major NDs and what causes them?

3. What are the innovations in NDs?

4. What are the trends in drug development for NDs and what are the research clusters?

5. How are companies expanding portfolios in the ND sector?

6. What are the leading drugs and classes for Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and Parkinson's disease?

7. What are the key drivers of innovation in NDs?

8. What are the sales forecasts for NDs to 2014?

9. How are companies responding to patent expiries of leading products?

10. What are the current activities of companies in relation to cell therapies for NDs?

11. How are biologics developing for NDs and which areas of ND are most likely to benefit?

12. What are the advantages and disadvantages of leading and pipeline products?

13. How are products positioned in the global landscape and what are the current trends in R&D?

14. What are the activities of companies developing innovative therapies for NDs?

15. What are the research and market opportunities for NDs?

For more information, please contact :

http://www.aarkstore.com/reports/The-Market-Outlook-for-Neurodegenerative-Diseases-Epidemiology-market-size-current-treatments-and-future-innovation--65427.html

Contact : minu

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Aarkstore Enterprise -The Market Outlook for Neurodegenerative Diseases: Epidemiology, market size,

By: Minal

POST COMMENT

Aarkstore Enterprise - Periodontal Disease - Pipeline Assessment and Market Forecasts to 2017 Pure Acai Berry– A Natural Product Full of Health Benefits Ayurvedic Home Remedies for a Healthy Body and Mind Aarkstore Enterprise - Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016 Winter Pool Covers – A Hot Way of Maintaining Your Pool Top 5 Most Effective Ways To Lose Body Fat Pet Wellness - Natural Pet Health Care for Sore Muscles & Joints Cure Sweaty Palms For Good - Sweat Busting Tips New Choice for Winter Outfits Body Sculpting System - Best Offer How to Build Muscles by Perfect Diet - Is Healthy Diet Essential for Getting Larger Biceps Organic herbal Ayurvedia remedies are very useful in curing AIDS/HIV Understanding The Most Common Cat Health Problems